Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
531 results
  • Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. [Journal Article]
  • JACCJ Am Coll Cardiol 2019 Jun 18; 73(23):2961-2970
  • Charytan DM, Sabatine MS, … FOURIER Steering Committee and Investigators
  • CONCLUSIONS: LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633).
  • Status of PCSK9 Monoclonal Antibodies in Australia. [Review]
  • HLHeart Lung Circ 2019 May 08
  • Scherer DJ, Nelson AJ, … Watts GF
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to red…
New Search Next